{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:02:56Z","timestamp":1773928976985,"version":"3.50.1"},"reference-count":36,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BCTT"],"DOI":"10.2147\/bctt.s341857","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T05:00:11Z","timestamp":1649739611000},"page":"101-111","source":"Crossref","is-referenced-by-count":9,"title":["Ribociclib in the Treatment of Hormone-Receptor Positive\/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Maria Chiara","family":"Parati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Pedersini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-4946","authenticated-orcid":true,"given":"Gianluca","family":"Perego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Reduzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Savio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Cabiddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Borgonovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":true,"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.353","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"key":"ref2","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with HR+\/HER2- advanced breast cancer treated with endocrine Therapy \u00b1 Ribociclib. Presented at: ESMO Congress; September 16\u201321; 2021."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Yardley D, Chan A, Nusch A, et al. Ribociclib plus endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: subgroup analysis of Phase 3 MONALEESA trials. Presented at: San Antonio Breast Cancer Symposium; San Antonio, TX, USA; 4\u20138 December; 2018.","DOI":"10.1158\/1538-7445.SABCS18-P6-18-07"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Blackwell KL, Paluch-Shimon S, Campone M, et al. Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the Phase III MONALEESA-2 study. Presented at: San Antonio Breast Cancer Symposium; TX, USA; 5\u20139 December; 2017.","DOI":"10.1158\/1538-7445.SABCS17-P5-21-18"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-017-4658-x","volume":"169","author":"Janni","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","first-page":"54","volume":"4","author":"Lu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2217\/fon-2019-0130","volume":"15","author":"Yardley","year":"2019","journal-title":"Future Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14740338.2021.1931116","volume":"20","author":"Leung","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-018-4769-z","volume":"170","author":"Verma","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0959-8049(18)30260-0","volume":"92","author":"Harbeck","year":"2018","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10549-021-06334-0","volume":"189","author":"De Laurentiis","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11864-019-0651-4","volume":"20","author":"Murphy","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2019.05.010","volume":"19","author":"Goel","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41523-021-00311-y","volume":"7","author":"Spring","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000481657","volume":"12","author":"Schettini","year":"2017","journal-title":"Breast Care"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1158\/1078-0432.CCR-20-0645","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2021.11.025","volume":"162","author":"Peuker","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref28","unstructured":"Pembrolizumab, Letrozole, and Palbociclib in treating postmenopausal patients with newly diagnosed metastatic stage IV estrogen receptor positive breast cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02778685. Accessed January 12, 2022."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432.CCR-18-1999","volume":"25","author":"Ameratunga","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1200\/jco.2020.38.15_suppl.531","volume":"38","author":"Spring","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","volume":"125","author":"Burris","year":"2021","journal-title":"Br J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1245\/s10434-015-4405-7","volume":"22","author":"Haddad","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.breast.2016.06.008","volume":"25","author":"Curigliano","year":"2016","journal-title":"Breast"},{"key":"ref34","first-page":"abs 505","author":"Khan","year":"2020","journal-title":"Proc Am Soc"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","volume":"8","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet"}],"container-title":["Breast Cancer: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=79884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=79884","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T05:00:22Z","timestamp":1649739622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/ribociclib-in-the-treatment-of-hormone-receptor-positiveher2-negative--peer-reviewed-fulltext-article-BCTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":36,"URL":"https:\/\/doi.org\/10.2147\/bctt.s341857","relation":{},"ISSN":["1179-1314"],"issn-type":[{"value":"1179-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}